Alivus Life Sciences Limited has issued an update regarding the recovery timeline following a fire incident at its Dahej manufacturing facility. The company provided detailed information about the extent of damage and expected resumption of operations under Regulation 30 of SEBI Listing Regulations.

Incident Assessment and Impact

The fire incident occurred on February 14, 2026, at the company's manufacturing facility located in Dahej, Bharuch district, Gujarat. The incident was confined to one of seven production blocks at the facility and affected only a portion of the intermediate manufacturing facilities within that block.

Production Resumption Timeline

Alivus Life Sciences has provided a clear timeline for resuming operations at the affected production block. The company expects to restart different manufacturing processes in phases based on the assessment of damage and recovery requirements.

The temporary cessation of manufacturing operations will result in a few delayed shipments, though the company has not specified the exact impact on delivery schedules or financial implications.

Safety Measures and Protocols

The company emphasized its commitment to safety standards across all operations. Alivus Life Sciences stated that safety is of paramount importance and confirmed that it follows stringent safety standards and protocols across its operations. The company continues to implement necessary precautionary measures to prevent similar incidents in the future.

Facility Operations Status

Despite the incident in one production block, the majority of the Dahej facility remains operational. All other six production blocks at the site are unaffected and continue normal operations, ensuring minimal disruption to the company's overall manufacturing capacity. The Active Pharmaceutical Ingredient manufacturing facilities within the affected block also remained undamaged, limiting the scope of production interruption.

Alivus Life Sciences Limited has delivered its strongest quarterly performance to date, reporting record-breaking financial results for Q3 FY26 ended December 31, 2025. The pharmaceutical company achieved significant milestones across revenue growth, profitability, and operational efficiency during the quarter.

Record Financial Performance

The company reported its highest-ever quarterly revenue of Rs. 673 crores, representing substantial growth momentum with 14.4% quarter-on-quarter and 4.8% year-on-year expansion. This performance was driven by strong contributions across all business segments, with particular strength in regulated markets including Europe, Japan, LATAM, and India.

Exceptional Margin Expansion

Alivus achieved record EBITDA margins of 36.4% for the quarter, marking a significant improvement of 340 basis points quarter-on-quarter and 510 basis points year-on-year. The gross margin reached 58.9%, up 330 basis points year-on-year, driven by new product launches, favorable product mix, and enhanced operational efficiencies. PAT margins stood at 22.3% for the quarter.

Nine-Month Performance Highlights

For the nine-month period FY26, the company demonstrated consistent growth trajectory:

The non-GPL business segment showed particularly strong performance with 16.1% growth, reflecting the underlying strength of the company's diversified business model across geographies.

CDMO Business Recovery

The Contract Development and Manufacturing Organization (CDMO) segment delivered exceptional performance, achieving 100% quarter-on-quarter and 85.3% year-on-year growth. This recovery was driven by robust traction in newer CDMO projects, with Project 4 and Project 5 contributing significantly to revenue expansion as expected in the second half turnaround.

Strong Balance Sheet and Cash Position

Alivus maintained its debt-free status with strong financial fundamentals:

Capacity Expansion and R&D Pipeline

The company's expansion initiatives at Solapur, Ankleswar, and Dahej are progressing as planned. CAPEX guidance for FY26 has been revised to Rs. 450 crores from the earlier Rs. 600 crores, with Rs. 150 crores deferred to FY27. The robust pipeline includes 595 DMF and CEP filings globally, with the high potent API portfolio comprising 27 products representing a total addressable market of $70 billion.

Therapeutic Portfolio Performance

CVS and CNS therapies continued to lead growth, contributing 51% to the topline, while chronic therapies represented 66% of Q3 FY26 revenue. R&D expenditure remained at 3.4% of sales for the quarter and 3.5% for nine months.

Forward Guidance

Management expects high single-digit revenue growth for FY26, driven by strong performance across diversified non-GPL segments and continued CDMO project ramp-up. EBITDA margins are expected to range between 30%-32% going forward, representing an upward revision from the earlier guidance of 28%-30%, supported by operational efficiencies and new product launch contributions.